Skip to main
IVVD

Invivyd Inc (IVVD) Stock Forecast & Price Target

Invivyd Inc (IVVD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Invivyd is tackling the global issue of viral infections by utilizing their expertise in monoclonal antibody (mAb) therapies. Their lead product, PEMGARDA, has already received FDA authorization for pre-exposure prevention of COVID-19 in immunocompromised individuals, and they have a strong pipeline of next-generation antibodies targeting various viral diseases. The company also has a strong potential for commercial success, with a promising development and regulatory pathway for their products. With enrollment complete for their Phase 3 DECLARATION study, and sufficient events recorded for a positive result, the focus now shifts to VYD2311 and its expected positive results, which have the potential to propel the stock forward.

Bears say

Invivyd is heavily focused on monoclonal antibody therapies for the treatment and prevention of viral infectious diseases, with its lead product receiving FDA approval for pre-exposure prevention of COVID-19 in certain immunocompromised individuals. However, the current upward trend in COVID-19 transmission and hospitalizations, as well as the company's reliance on a single product for commercial success, raise concerns about its financial performance in the short-term. This, combined with potential risks in clinical readouts and regulatory uncertainties, may make Invivyd's stock a risky investment option.

Invivyd Inc (IVVD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Invivyd Inc (IVVD) Forecast

Analysts have given Invivyd Inc (IVVD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Invivyd Inc (IVVD) has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Invivyd Inc (IVVD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.